FDA red and green lights: June 2025
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
A second shot at PARP1 from Eikon
The private US biotech features among recent first-in-human study entrants, with another PARP1-selective molecule.
Oric looks over its shoulder
Tough equity markets as well as competitor developments prompt a narrowed focus.
Boehringer beats Bayer to the regulators
The FDA will rule on a low dose of zongertinib in the summer.
Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
Novartis’s post-Pluvicto plan materialises
The company has two actinium-labelled PSMA radiopharmaceuticals, and one is about to pivotal.
Targeted lung cancer niche sees a German pharma battle
But could toxicity be holding back filing plans?
